Landogrozumab (INN; development code LY2495655) is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders.
[1][2] The drug was developed by Eli Lilly and Company.
This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.